12 To 15 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.5)
  • Uses of Natriuretic Peptide Constructs
    Publication number: 20130274207
    Abstract: Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or COPD, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.
    Type: Application
    Filed: October 17, 2012
    Publication date: October 17, 2013
    Applicant: PALATIN TECHNOLOGIES, INC.
    Inventors: Margarita Bastos, Jennifer Lata, Jeffrey D. Edelson
  • Compositions and Methods for Promoting Wound Healing and Tissue Regeneration
    Publication number: 20130274206
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Applicant: MUSC Foundation for Research Development
    Inventor: MUSC Foundation for Research Development
  • Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20130273169
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Peptides for Treating Cancer
    Publication number: 20130274202
    Abstract: The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX1X2X1 motif (SEQ ID NO: 1), wherein each X1 independently is M or Nle and X2 is any amino acid, pharmaceutical compositions comprising said peptide and use thereof for treating cancer.
    Type: Application
    Filed: December 12, 2011
    Publication date: October 17, 2013
    Applicant: GENE SIGNAL INTERNATIONAL SA
    Inventors: Salman Al-Mahmood, Sylvie Colin
  • MOESIN MODULATORS AND USES THEREOF
    Publication number: 20130266537
    Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.
    Type: Application
    Filed: October 8, 2011
    Publication date: October 10, 2013
    Applicant: SHANGHAI KEXIN BIOTECH CO., LTD.
    Inventors: Yue Zhang, Jun Bao, Hua Mao, Zhinan Shou, Weina Situ
  • Pharmaceutical preparations and methods for inhibiting tumors
    Patent number: 8551951
    Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: October 8, 2013
    Assignee: Aenorasis SA Pharmaceuticals and Medical Devices
    Inventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
  • IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
    Patent number: 8546321
    Abstract: The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: October 1, 2013
    Assignee: Kobenhavns Universitet
    Inventors: Elisabeth Bock, Vladimir Berezin
  • Thrombospondin-1 derived peptides and treatment methods
    Patent number: 8546323
    Abstract: Treatments employing the matricellular protein thrombospondin-1 (TSP-I) and related compositions are disclosed for stabilizing atherosclerotic plaque and decreasing occurrence of plaque rupture events leading to, for example, myocardial infarction, stroke, and acute limb ischemia. Various peptides, including certain synthetic peptides, related to TSP-I are also disclosed. Such peptides have utility in stabilizing plaque in various contexts, including the disease states mentioned above. Some of these peptides include one or more sequences related to active sites of TSP-I for regulating, e.g., TGF-ss1 and MMP-9 activity. Experimental data show that a representative peptide provides a beneficial effect with systemic injection of the peptide.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: October 1, 2013
    Inventor: Ramtin Agah
  • PLIF MULTIMERIC PEPTIDES AND USES THEREOF
    Publication number: 20130252905
    Abstract: Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of Placenta Immunomodulatory Factor (PLIF) to human leukocytes.
    Type: Application
    Filed: March 10, 2013
    Publication date: September 26, 2013
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventor: Chaya MOROZ
  • Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3
    Patent number: 8541376
    Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: September 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Hans-Peter Gerber, Joe Kowalski, Maria Teresa Pisabarro, Daniel Eric Sherman
  • COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20130244946
    Abstract: Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 19, 2013
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Ronit SHALTIEL-KARYO, Ehud Gazit
  • VIP FRAGMENTS AND METHODS OF USE
    Publication number: 20130244934
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.
    Type: Application
    Filed: May 28, 2013
    Publication date: September 19, 2013
    Applicant: Vectus Biosystems Limited
    Inventor: Karen Annette Duggan
  • Treatment for anxiety
    Patent number: 8536129
    Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: September 17, 2013
    Assignee: NoNO Inc.
    Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
  • HUMAN-DERIVED CELL-PERMEABLE PEPTIDE BIOACTIVE PEPTIDE CONJUGATE, AND USE THEREOF
    Publication number: 20130237484
    Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.
    Type: Application
    Filed: April 25, 2011
    Publication date: September 12, 2013
    Applicants: Nanao Intelligent Biomedical Engineering Corporation Co., Ltd., Seoul National University R&DB Foundation
    Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, Jin Sook Suh
  • ADIPOSE TISSUE TARGETED PEPTIDES
    Publication number: 20130237476
    Abstract: The application provides synthetic peptide conjugates capable of targeting and causing ablation of adipose tissue in mammal comprising at least one targeting peptide and at least one therapeutic peptide. The synthetic peptide conjugates are envisaged to have decreased physiological toxicity and/or enhanced in situ cytotoxicity compared to the peptide CKGGRAKDC-GG-D(KLAKLAKKLAKLAK) (SEQ ID NO: 2).
    Type: Application
    Filed: March 5, 2013
    Publication date: September 12, 2013
    Applicant: ABLARIS THERAPEUTICS INC.
    Inventor: James F. HULVAT
  • Methods and compositions for treating conditions
    Patent number: 8530432
    Abstract: The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: September 10, 2013
    Assignee: NeoPro Labs, LLC
    Inventor: Hanna Skubatch
  • Pharmaceutical formulation
    Patent number: 8524673
    Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: September 3, 2013
    Assignee: KAI Pharmaceuticals, Inc.
    Inventor: Mike Tso-ping Li
  • Treatment of bacterial infections
    Patent number: 8524861
    Abstract: The invention relates to polypeptides, comprising repeats of peptides derived from apolipoproteins, which exhibit antibacterial activity and to nucleic acids encoding the same. The invention further provides the use of such polypeptides, derivatives, analogues or nucleic acids as medicaments, and also their use in methods of preventing or treating bacterial infection or objects and surfaces. The invention further extends to objects, such as contact lenses, coated with the polypeptides.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: September 3, 2013
    Assignee: AI2 Limited
    Inventors: Curtis Dobson, Keith Alan Crutcher
  • Antidiabetic Comppounds
    Publication number: 20130225488
    Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.
    Type: Application
    Filed: September 28, 2007
    Publication date: August 29, 2013
    Inventors: Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
  • Skin permeating and cell entering (SPACE) peptides and methods of use thereof
    Patent number: 8518871
    Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: August 27, 2013
    Assignee: The Regents of the University of California
    Inventors: Tracy Hsu, Samir M. Mitragotri
  • Human milk peptides
    Patent number: 8518894
    Abstract: The present invention provides for novel peptides derived from human milk. In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: August 27, 2013
    Inventors: Kenneth James Friel, Apollinaire Tsopmo
  • CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTEC USES
    Publication number: 20130216504
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Application
    Filed: December 21, 2012
    Publication date: August 22, 2013
    Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
    Inventor: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
  • PEPTIDES ABLE TO INTERFERE WITH THE INHIBITING ACTIVITY OF MDM2/MDM4 HETERODIMER TOWARDS P53 AND USE THEREOF FOR CANCER TREATMENT
    Publication number: 20130217634
    Abstract: The present disclosure concerns peptides able to interfere and in particular impair the inhibiting activity of MDM2/MDM4 heterodimer towards p53 and maintain the association between MDM4 and p53 so to restore the p53 oncosuppressive function in cancer cells harboring wild type p53 protein, directing its function specifically towards an apoptotic outcome.
    Type: Application
    Filed: February 21, 2013
    Publication date: August 22, 2013
    Applicants: UNIVERSITA' DEGLI STUDI DI PERUGIA, CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventors: CONSIGLIO NAZIONALE DELLE RICERCHE, UNIVERSITA' DEGLI STUDI DI PERUGIA
  • CXCR4 Receptor Compounds
    Publication number: 20130210709
    Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.
    Type: Application
    Filed: November 4, 2009
    Publication date: August 15, 2013
    Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
  • Polypeptide TF1 for Inhibiting Type 2 Shiga Toxin Activity, Encoding Gene for Same and Use Thereof
    Publication number: 20130210750
    Abstract: The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for the same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in Sequence 1 in the sequence list. The polypeptide P1 can be prepared into medicine for preventing and/or treating diseases caused by type-2 Shiga toxin or the pathogens which produce type-2 Shiga toxin.
    Type: Application
    Filed: September 9, 2011
    Publication date: August 15, 2013
    Applicant: Institute of Microbiology and Epidemiology Academy of Military Medical Sciences
    Inventors: Hui Wang, Tao Li, Qin Wang, Wei Tu, Xiaojun Hou
  • PEPTIDES, CONSTRUCTS AND USES THEREFOR
    Publication number: 20130210749
    Abstract: The invention provides novel peptides and constructs. In addition the invention provides methods for carrying compounds across the cell membrane, for antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein.
    Type: Application
    Filed: June 10, 2011
    Publication date: August 15, 2013
    Applicant: Auckland Uniservices Limited
    Inventor: Geoffrey Wayne Krissansen
  • Peptide modulators of angiogenesis and use thereof
    Patent number: 8507434
    Abstract: Compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators are described. As discussed in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: August 13, 2013
    Assignee: The Johns Hopkins University
    Inventors: Aleksander S. Popel, Emmanouil D. Karagiannis
  • Treatments for gastrointestinal disorders
    Patent number: 8507447
    Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: August 13, 2013
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
  • PROTEASE TARGETING AGENTS
    Publication number: 20130203685
    Abstract: Peptides having the ability to block the activity of acyl-aminoacid releasing enzymes such as AARE or APEH are disclosed. Derivatives of the peptides include oligomers or multimers of the peptide linked to a common scaffold moiety such as a tri-functional amino acid and peptides linked to PEG and fatty acids. Pharmaceutical compositions that include the peptide are also disclosed and can be used to treat various diseases such as cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases.
    Type: Application
    Filed: February 27, 2013
    Publication date: August 8, 2013
    Applicant: CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventor: Consiglio Nazionale delle Ricerche
  • Methods of reducing inflammation and mucus hypersecretion
    Patent number: 8501911
    Abstract: Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: August 6, 2013
    Assignees: Biomarck Pharmaceuticals, Ltd, North Carolina State University
    Inventors: Yuehua Li, Linda D. Martin, Kenneth B. Adler, Shuji Takashi, Indu Parikh
  • Peptide toxin formulation
    Patent number: 8501684
    Abstract: Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: August 6, 2013
    Assignee: Vestaron Corporation
    Inventors: William Tedford, John McIntyre, Daniel Russell, Peter Carlson
  • PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME
    Publication number: 20130190233
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 25, 2013
    Applicant: CUREDM GROUP HOLDINGS, LLC
    Inventor: CUREDM GROUP HOLDINGS, LLC
  • Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
    Patent number: 8492347
    Abstract: The present invention relates to D-amino acid peptides and their use in methods for the diagnosis and/or treatment of immune disorders such as systemic lupus erythematosus.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: July 23, 2013
    Assignee: The Regents of the University of California
    Inventors: Bevra H. Hahn, Fanny M. Ebling, Antonio La Cava, Ram Raj Singh, Ram Pyare Singh
  • Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
    Patent number: 8491891
    Abstract: A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 23, 2013
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger, Kai-Chuan Chen, Zeljko Prijovic
  • EXTRACT AND PEPTIDES DERIVED FROM ORYZA SATIVA JAPONICA GROUP AND USES THEREOF
    Publication number: 20130184219
    Abstract: The invention relates to isolated peptides derived from Oryza sativa Japonica Group, pharmaceutical compositions comprising same, and uses thereof for treating, preventing, ameliorating, and/or delaying the onset of inflammatory and/or neuroinflammatory and/or autoimmune diseases or conditions and in particular multiple sclerosis. The invention further relates to extracts from Oryza sativa Japonica Group and use thereof as a dietary supplement or in a pharmaceutical composition for treating, preventing, ameliorating, and/or delaying the onset of inflammatory, and/or inflammatory, neuroinflammatory and/or autoimmune diseases or conditions. The peptides and the extract of the invention may be used for treating, ameliorating, and/or delaying the onset or preventing multiple sclerosis.
    Type: Application
    Filed: June 29, 2010
    Publication date: July 18, 2013
    Inventor: Uri Wormser
  • Immunity to folate receptors
    Patent number: 8486412
    Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: July 16, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
  • Compounds for the treatment of diseases related to protein misfolding
    Patent number: 8481494
    Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: July 9, 2013
    Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
  • GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20130172242
    Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.
    Type: Application
    Filed: June 16, 2011
    Publication date: July 4, 2013
    Applicants: MCGILL UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
  • Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof
    Publication number: 20130172272
    Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.
    Type: Application
    Filed: February 20, 2013
    Publication date: July 4, 2013
    Applicant: Medical Diagnostic Laboratories
    Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
  • Leptin agonist and methods of use
    Patent number: 8470772
    Abstract: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, insulin resistance, lipodystrophy and hypothalamic amenorrhea, anorexia-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: June 25, 2013
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Eva Surmacz, Laszlo Otvos, Jr.
  • Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
    Patent number: 8470783
    Abstract: A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: June 25, 2013
    Assignee: Astellas Pharma Inc.
    Inventors: Yuka Sasakawa, Yoshinori Naoe
  • Novel Peptides for Wound Healing
    Publication number: 20130157949
    Abstract: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition comprising them and their use for wound healing.
    Type: Application
    Filed: June 14, 2011
    Publication date: June 20, 2013
    Applicant: GENE SIGNAL INTERNATIONAL SA
    Inventors: Salman Al-Mahmood, Sylvie Colin
  • LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE
    Publication number: 20130157961
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 20, 2013
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter
  • SENSITIZATION OF TUMOR CELLS TO RADIATION THERAPY THROUGH ADMINISTRATION OF ENDOTHELIN AGONISTS
    Publication number: 20130150649
    Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
    Type: Application
    Filed: February 6, 2013
    Publication date: June 13, 2013
    Applicants: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinois
    Inventors: The Board of Trustees of the University of Illinois, Spectrum Pharmaceuticals, Inc.
  • Polypeptides for the Treatment or Prevention of Cancer and uses Thereof
    Publication number: 20130149372
    Abstract: Disclosed herein are polypeptides or their derivatives and their application. The polypeptides and their derivatives can treat or prevent cancer. The polypeptides of the invention have significant lethality to the cancer cells when used alone. When its clinical commonly used chemotherapy drugs such as cisplatin in combination, it can significantly increase the sensitivity of chemotherapeutic agents on cancer cells, to enhance its lethality of cancer cells, to reduce the dosage. The peptides can kill a variety of cancer cells, but without apparent toxicity enhancing effect on normal cells. The prepared peptides of the present invention can be chemically synthesized, high-purity, low molecular weight, specificity, non-immunogenic, safe and reliable.
    Type: Application
    Filed: September 29, 2010
    Publication date: June 13, 2013
    Applicant: WUHAN KATYGEN PHARMACEUTICALS,INC.
    Inventors: Jianhua Chen, Yi Huang, Junyu Xiong, Caihong Chen
  • Novel Peptides and Uses Thereof
    Publication number: 20130149245
    Abstract: The invention relates to a peptide of 8-50 amino acids comprising the sequence of KAHKKRAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising the sequence of HKKR or RKKH. Also disclosed are methods of using the peptide for detecting, monitoring, or treating cancer.
    Type: Application
    Filed: September 20, 2012
    Publication date: June 13, 2013
    Applicants: CHILDREN'S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: UNIVERSITY OF SOUTHERN CALIFORNIA, CHILDREN'S HOSPITAL LOS ANGLES
  • AVß6 PEPTIDE LIGANDS AND THEIR USES
    Publication number: 20130149248
    Abstract: AV?6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV?6 mediated diseases.
    Type: Application
    Filed: January 17, 2013
    Publication date: June 13, 2013
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventor: CANCER RESEARCH TECHNOLOGY LIMITED
  • Agents that modulate Eph receptor activity
    Patent number: 8461119
    Abstract: Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: June 11, 2013
    Assignee: The Burnham Institute
    Inventors: Elena B. Pasquale, Mitchell Koolpe, Keith K. Murai
  • Surface protection of exposed biological tissues
    Patent number: 8461104
    Abstract: The invention relates to a biodegradable barrier network comprising at least two polypeptides, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator or kit in therapy, such as in medicine, veterinary medicine and horticulture.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: June 11, 2013
    Assignee: Bioactive Polymers AB
    Inventors: Stig Bengmark, Kåre Larsson, Björn Lindman, Roland Andersson
  • Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
    Patent number: 8455450
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: June 4, 2013
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham